Conditions: Breast Cancer Non-Small-Cell Lung Cancer Glioblastoma Other Cancers
Keywords: Healthy volunteers
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 27
Healthy volunteers: yes

Brief summary:
The purpose of the study was to conduct a pilot test of new tracers (\[18F\]FPRGD2 and \[18F\]FPPRGD2) to define normal tracer biodistribution (where the tracer goes), stability (how much metabolises), pharmacokinetics (how much stays in which organs and for how long), and radiation dosimetry (organ radiation dose). Healthy volunteers provided the normal biodistribution data.

The same radiopharmaceutical was also tested in breast cancer, glioblastoma multiform (brain cancer), and lung cancer.

Detailed description:
The tracer \[18F\]FPRGD2 was not evaluated in this study. The protocol title was never amended to reflect this.

Arms:
arm 1: Normal volunteers to receive 5 to 14 mCi F18-FPPRGD2 by intravenous (IV) injection. arm 2: Breast cancer patients to receive 4 to 11 mCi F18-FPPRGD2 by IV injection. arm 3: Glioblastoma multiform patients to receive 5 to14 mCi F18-FPPRGD2 by IV injection. arm 4: Lung cancer patients to receive X to XX mCi F18-FPPRGD2 by IV injection.

Interventions: intervention 1: F18-FPPRGD2
Intervention descriptions: intervention 1: Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).

Protocol document: